Evidence map›Paper›PMID 33407605›Full record

ArticleJournal of translational medicine2021

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).

Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, Bruno Daniele, Michael Dougan, Leisha A Emens, Silvia Formenti, Filip Janku, Samir N Khleif, Tomas Kirchhoff and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. A deformableMaterials today. Bio · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Paolo A AsciertoCancer Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com.ORCID 0000-0002-8322-475X
Lisa H ButterfieldPICI Research & Development, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Katie CampbellPICI Research & Development, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Bruno DanieleOncology Unit, Ospedale del Mare, Naples, Italy.
Michael DouganMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Leisha A EmensUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Silvia FormentiSandra and Edward Meyer Cancer Center, Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Filip JankuDivision of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samir N KhleifThe Loop Immuno-Oncology Research Laboratory, Lombardi Cancer Center, Georgetown University, Washington, DC, USA.
Tomas KirchhoffPerlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
Alessandro MorabitoThoracic Medical Oncology, National Cancer Institute, IRCCS-Fondazione G. Pascale, Naples, Italy.
Yana NajjarUPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Paul NathanMount Vernon Cancer Centre, Northwood, UK.
Kunle OdunsiCenter for Immunotherapy and Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Akash PatnaikSection of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
Chrystal M PaulosWinship Cancer Institute at Emory University, Atlanta, GA, USA.
Bradley I ReinfeldVanderbilt University Medical Center, Nashville, TN, USA.
Heath D SkinnerDepartment of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
John TimmermanUniversity of California, Los Angeles, Los Angeles, CA, USA.
Igor PuzanovRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Funding

Metabolic Contributions of Individual Cellular Compartments to the Diversity of the Tumor Microenvironment in Renal Cell CarcinomaF30CA247202 · NCI · VANDERBILT UNIVERSITY · PI REINFELD, BRADLEY · 2021 to 2023
$107k
NCI NIH HHS F30 CA247202
6 · The paper itself

Abstract

Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4-5 December, 2019, Naples, Italy), and are summarised in this report.

Indexed as

Biomarkers, TumorMelanomaHumansImmunotherapyItalyMedical OncologyBiomarkers, TumorBiomarkersCheckpoint inhibitorsCombination therapyImmunotherapyTumor microenvironmentVaccine

Identifiers

PMID33407605
PMCPMC7789268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.